FLAME 2020
Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets
Report Highlights
The global liquid biopsy market should reach $6.1 billion by 2023 from $2.4 billion in 2018 at a compound annual growth rate (CAGR) of 20.8% for the period 2018 to 2023.
Report Includes
- 32 data tables and 54 additional tables
- Industry analysis of the liquid biopsy biomarkers and technologies market
- Analyses of global market trends with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Characterization and quantification of market potential for liquid biopsy diagnostics by application, biomarker type, analysis platform, analysis purpose and geographical region
- Discussion of several significant large-scale research initiatives that are contributing to liquid biopsy market development
- Examination of various conventional biopsy methods and highlight how liquid biopsy enabling technologies address the issues and are gaining significant traction with key opinion leaders
- Coverage of significant patents and their allotments in each category, as well as major industry acquisitions and strategic alliances data
- Company profiles of major manufacturers and suppliers of liquid biopsy research tools, services and diagnostics, including Agilent Technologies Inc., Cygnus Biosciences, Illumina Inc., Oxford Nanopore, Qiagen, Quantum Biosystems, Roche and Thermo Fisher Scientific
Report Scope
The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents, and companies. The market sizes for liquid biopsy diagnostics are given for 2017, 2018 and 2023 (forecasted).
This report reviews liquid biopsy biomarkers and technologies and provides background on why liquid biopsy is increasingly viewed as a replacement for, or a companion to, tissue biopsy. The report then discusses several of the significant large-scale research initiatives that are contributing to liquid biopsy development. Key forces driving the market are enumerated.
The structures of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from January 2017 through November 2018. Industry subsectors analyzed include advanced sequencing instruments; droplet digital PCR (polymerase chain reaction); target enrichment; single-cell DNA polymerase; non-invasive prenatal testing (NIPT); fetal-cell NIPT; CTC (circulating tumor cell) capture and detection; and liquid biopsy.
The market for liquid biopsy diagnostics is analyzed in depth. The market is analyzed by application (cancer, reproductive health, transplant), biomarker type (nucleic acids, cells, extracellular vesicles, proteins), analysis platform (microarray, NGS, PCR, proteomics, and other), analysis purpose (screening/early detection, diagnosis, therapy guidance, monitoring), and geography (North America, Europe, Asia/Pacific, Rest of World).
Market data covers 2017, 2018 and 2023 (forecasted).
More than 175 companies in the liquid biopsy industry are profiled in this report.
BCC Research provides a summary of the main industry acquisitions and strategic alliances from January 2017 through November 2018, including key alliance trends.
Analyst Credentials
John Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company, as well as executive management positions with a nanotechnology/separations company. Bergin holds a B.S. degree in Chemistry, an M.S. degree in Biotechnology and a Master of Business Administration. John Bergin is a pseudonym of the author.
Report Highlights
The global liquid biopsy market should reach $4.5 billion by 2022 from $1.5 billion in 2017 at a compound annual growth rate (CAGR) of 24.2%, from 2017 to 2022.
Report Includes
- An overview of the global markets for liquid biopsy research tools, services, and diagnostics
- Analyses of global market trends, with data from 2015 and 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
- Coverage of how these technologies can reduce invasive tumor biopsies, drive early cancer detection, and support precise drug administration
- Detailed analysis of liquid biopsy workflow technologies, biomarker classes, sample types, and research tools reagents
- Breakdowns of the market by product, product type, application, end use industry, technology, and indication
- Evaluation of the market's dynamics, specifically growth drivers, restraints, and opportunities
- Profiles of major players in the industry
Report Highlights
The global liquid biopsy market should reach nearly $4.5 billion in 2020 from $1.6 billion in 2015, registering a CAGR of 22.3% for the period of 2015-2020.
Report Includes
- An overview of the global markets for liquid biopsy research tools, services, and diagnostics
- Analyses of global market trends, with data for 2014, estimates for 2015, and projections of CAGRs through 2020
- Coverage of how these technologies can reduce invasive tumor biopsies, drive early cancer detection, and support precise drug administration
- Detailed analysis of liquid biopsy workflow technologies, biomarker classes, sample types, research tools reagents, and more
- Breakdowns of the market by product, product type, application, end use industry, technology, indication, as well as many others
- Evaluation of the market's dynamics, specifically growth drivers, restraints, and opportunities
- Profiles of major players in the industry